<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396019</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI 06-116</org_study_id>
    <nct_id>NCT00396019</nct_id>
    <nct_alias>NCT00678951</nct_alias>
  </id_info>
  <brief_title>Study of PEG-Intron for Plexiform Neurofibromas</brief_title>
  <official_title>A Phase II Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for slow growing tumors called plexiform neurofibromas (PNF) which are a
      relatively common problem in people with neurofibromatosis type 1 (NF1). These tumors are
      benign but as they grow, they can become disfiguring as well as disabling or even life
      threatening. They often cause pain, difficulty using arms or legs because of spinal cord
      compression, and/or nerve damage. At present, the only available therapy for plexiform
      neurofibromas is to try to surgically remove as much of the tumor as is possible. Because
      these tumors grow into the surrounding areas, total surgical resection is often impossible.
      Most tumors will re-grow after surgery if the entire tumor cannot be removed. To date, other
      treatments including chemotherapy and radiotherapy have not been able to shrink these tumors.

      Interferon is a drug that is used for different types of tumors as well as for hepatitis. It
      has been used in the treatment of plexiform neurofibromas (PNF) with some subjects showing
      improvement in symptoms and/or a decrease in the size of the tumor. Most subjects had no
      further growth of their tumor while on the PEG-Intron. The drug used in this study is PEG
      (pegylated)-Intron. PEG-Intron is a long acting form of interferon which keeps the drug from
      being broken down in the body for a longer period of time and potentially could be more
      effective than the short-acting interferon. PEG-Intron has been approved by the Food and Drug
      Administration (FDA) for the treatment of Hepatitis C.

      The goals of this study are:

        1. To determine how your child's plexiform neurofibroma responds to PEG-Intron when given
           weekly.

        2. To determine the side effects of PEG-Intron when given weekly to participants with
           plexiform neurofibromas.

        3. To evaluate a new method of measuring changes in the size of tumors called volume
           analysis. This method measures the entire volume of a tumor in three dimensions. The
           standard method of measuring tumors uses only the length and/or width of the tumor. By
           studying the different ways of measuring tumors the investigators hope to be able to
           determine which method is the most accurate and useful.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PEG-Intron will be given every week through a small needle under the skin, in the same way
      that insulin is given to people with diabetes. Subjects will be taught to do this at home. As
      long as the tumor isn't growing and the side effects are tolerable, the injections will be
      given once a week for 2 years.

      Children will be enrolled on the study into one of three strata (patient groups): strata 1
      includes children who do not have any symptoms associated with their PNF and MRI scans over
      the past year may or may not show tumor growth, strata 2 includes children who have symptoms
      associated with the PNF but MRI scans over the past year have not shown growth and strata 3
      includes children who have shown an increase in the size of the PNF on MRI scans over the
      past year, with or without any symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2006</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Imaging Response in Strata 1 and 2</measure>
    <time_frame>MRI scans were performed at baseline and at months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study.</time_frame>
    <description>A response was defined as a ≥20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma ( PN) within 12 months confirmed by a follow-up MRI after ≥4 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response in Stratum 2</measure>
    <time_frame>baseline, week 6, months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
    <description>Clinical response was defined as a protocol-specified improvement in ophthalmologic evaluation, an improvement of at least one level in performance status (PS) ≥50% decrease in the amount of pain medications required per week compared with baseline or ability to change from a narcotic to a nonnarcotic analgesic, sustained for at least one month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Progression (TTP) in Stratum 3</measure>
    <time_frame>baseline, week 6, months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
    <description>TTP was estimated by the Kaplan-Meter method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Imaging Response in Stratum 3</measure>
    <time_frame>MRI scans were performed at baseline and at months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
    <description>A Response was defined as a ≥ 20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma (PN) within 12 months, confirmed by a follow-up MRI after ≥ 24 weeks</description>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Plexiform Neurofibroma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Intron</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or equal to 18 months to 21 years

          -  Diagnosis Patients with NF1 and progressive, symptomatic or life-threatening plexiform
             neurofibromas which are not surgically resectable. Patients without biopsy-proof of
             plexiform must have at least one other diagnostic criteria for NF1: 6 or more
             cafe-au-lait spots, freckling in the axilla or groin, optic glioma, 2 or more Lisch
             nodules, distinctive bony lesion, first degree relative with NF1.

          -  Only eligible if complete tumor resection is not feasible, or if a patient with a
             surgical option refuses surgery.

          -  Patients may be treated on this trial without having received prior therapy. If
             patients have received prior therapy, they must have recovered from all toxic effects
             prior to entering this study.

          -  Must have life expectancy of at least 12 months and a performance score (Karnofsky or
             Lansky) of &gt; or equal to 50.

          -  Must have adequate liver, kidney and bone marrow function

        Exclusion Criteria:

          -  Clinically significant unrelated systemic illness.

          -  Received an investigational agent within the past 30 days.

          -  Evidence of active visual pathway glioma

          -  History of malignant peripheral nerve sheath tumor or ther cancer other than
             surgically cured non-melanoma skin cancer or cervical carcinoma in situ

          -  Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, or
             immunotherapy.

          -  Inability to return for follow-up visits or obtain follow-up studies

          -  Severe cardiovascular disease

          -  Pre-existing sever psychiatric condition or history of psychiatric disorder requiring
             hospitalization or a history of suicidal ideation or attempt.

          -  Thyroid dysfunction not responsive to therapy.

          -  Uncontrolled diabetes mellitus

          -  History of seropositivity for HIV

          -  Subjects who are pregnant, lactating, or of reproductive potential and not practicing
             an effective means of contraception.

          -  Any medical condition requiring chronic systemic corticosteroids.

          -  Subjects who are known to be actively abusing alcohol or drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Tersak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, Pollack IF, Goodwin A, Manley PE, Fangusaro J, Allen R, Widemann BC. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017 Feb 1;19(2):289-297. doi: 10.1093/neuonc/now158.</citation>
    <PMID>27510726</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <results_first_submitted>August 9, 2017</results_first_submitted>
  <results_first_submitted_qc>October 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jean M. Tersak, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stratum 1 No Symptom With or Withour Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="P2">
          <title>Stratum 2 Symptoms no Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="P3">
          <title>Stratum 3 Tumor Growth With or Without Symptoms</title>
          <description>Peg-intron given every week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stratum 1 No Symptom With or Withour Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="B2">
          <title>Stratum 2 Symptoms no Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="B3">
          <title>Stratum 3 Tumor Growth With or Without Symptoms</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>Age data is missing for one subject.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than 5 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 to 12 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to 12 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Gender data was not captured with demographic/enrollment data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Imaging Response in Strata 1 and 2</title>
        <description>A response was defined as a ≥20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma ( PN) within 12 months confirmed by a follow-up MRI after ≥4 weeks.</description>
        <time_frame>MRI scans were performed at baseline and at months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study.</time_frame>
        <population>Not specified</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1 No Symptom With or Withour Tumor Growth</title>
            <description>Peg-intron given every week</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2 Symptoms no Tumor Growth</title>
            <description>Peg-intron given every week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Imaging Response in Strata 1 and 2</title>
          <description>A response was defined as a ≥20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma ( PN) within 12 months confirmed by a follow-up MRI after ≥4 weeks.</description>
          <population>Not specified</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response in Stratum 2</title>
        <description>Clinical response was defined as a protocol-specified improvement in ophthalmologic evaluation, an improvement of at least one level in performance status (PS) ≥50% decrease in the amount of pain medications required per week compared with baseline or ability to change from a narcotic to a nonnarcotic analgesic, sustained for at least one month.</description>
        <time_frame>baseline, week 6, months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
        <population>Only participants in Stratum 2 contributed data for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 2 Symptoms on Tumor Growth</title>
            <description>Peg-intron given every week</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response in Stratum 2</title>
          <description>Clinical response was defined as a protocol-specified improvement in ophthalmologic evaluation, an improvement of at least one level in performance status (PS) ≥50% decrease in the amount of pain medications required per week compared with baseline or ability to change from a narcotic to a nonnarcotic analgesic, sustained for at least one month.</description>
          <population>Only participants in Stratum 2 contributed data for this Outcome Measure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP) in Stratum 3</title>
        <description>TTP was estimated by the Kaplan-Meter method</description>
        <time_frame>baseline, week 6, months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
        <population>Only participants in Stratum 3 contributed data for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 3: Tumor Growth With or Without Symptoms</title>
            <description>Peg-intron given every week</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) in Stratum 3</title>
          <description>TTP was estimated by the Kaplan-Meter method</description>
          <population>Only participants in Stratum 3 contributed data for this Outcome Measure</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="7.1">¹not everyone experienced endpoint</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Imaging Response in Stratum 3</title>
        <description>A Response was defined as a ≥ 20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma (PN) within 12 months, confirmed by a follow-up MRI after ≥ 24 weeks</description>
        <time_frame>MRI scans were performed at baseline and at months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
        <population>Not Specified</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 3: Tumor Growth With or Without Symptoms</title>
            <description>Peg-intron given every week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Imaging Response in Stratum 3</title>
          <description>A Response was defined as a ≥ 20% reduction in the sum of the volume of the &quot;target&quot; plexiform neurofibroma (PN) within 12 months, confirmed by a follow-up MRI after ≥ 24 weeks</description>
          <population>Not Specified</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconfirmed Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during clinic visits at baseline, week 6, months 4, 8, 12, 18, and 24 while on treatment and every 6 months thereafter until off study</time_frame>
      <desc>Other</desc>
      <group_list>
        <group group_id="E1">
          <title>Stratum 1 No Symptom With or Withour Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="E2">
          <title>Stratum 2 Symptoms no Tumor Growth</title>
          <description>Peg-intron given every week</description>
        </group>
        <group group_id="E3">
          <title>Stratum 3 Tumor Growth With or Without Symptoms</title>
          <description>Peg-intron given every week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Fatugue</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title vocab="Allergic Reaction">Allergic Reaction</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <description>Transaminitis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Worsening behavior">Behavior</sub_title>
                <description>Behavior</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title vocab="Worsening depression">Depression</sub_title>
                <description>Worsening depression</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Regina Jakacki</name_or_title>
      <organization>AstraZeneca</organization>
      <email>regina.jakacki@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

